Efficacy of nintedanib ethanesulfonate soft capsules

Nintedanib (Nintedanib) is a new type of polytyrosine kinase inhibitor, mainly used to treat idiopathic pulmonary fibrosis (IPF). This drug exerts anti-fibrotic effects through multiple mechanisms and has gradually received attention and recognition from the medical community in recent years. Idiopathic pulmonary fibrosis is a chronic and progressive lung disease in which the patient's lung tissue is gradually replaced by fibrosis, resulting in a significant decline in respiratory function and seriously affecting the quality of life. Due to its long course and limited treatment options, the emergence of nintedanib ethanesulfonate offers new hope in the management of this disease.

One of the main mechanisms of action of nintedanib is to slow down the fibrosis process of lung tissue by inhibiting the excessive proliferation and activation of fibroblasts and reducing the expression of extracellular matrix (ECM) proteins. Studies have shown that nintedanib can down-regulate the protein and mRNA expression of important ECM components such as fibronectin and collagen 1A1, which is critical to preventing the further development of fibrosis. In addition, nintedanib can also inhibit transforming growth factor (TGF-β)-induced myofibroblast differentiation and further reduce the production of fibrosis-related markers.

In addition, nintedanib also has a certain impact on the autophagy process. Studies have found that nintedanib can induce beclin-1-dependent and ATG7-independent autophagy. Modulation of this autophagy mechanism may allow fibroblasts to become more effective in responding to environmental stress and promoting intracellular clearance of damaging substances, thereby indirectly supporting the improvement of lung function and tissue repair.

Nintedanib also interferes with the early events of the TGF-β signaling pathway, specifically by inhibiting the tyrosine phosphorylation of type II TGF-β receptor and the activation of SMAD3 and p38 mitogen-activated protein kinase, thereby enhancing its anti-fibrotic effect. This multiple mechanism of action indicates that nintedanib does not simply block a specific signal, but achieves its therapeutic effect by systematically modulating multiple signaling pathways.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC8613836/